These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12605799)

  • 21. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
    Tanis SP; Parker TT; Colca JR; Fisher RM; Kletzein RF
    J Med Chem; 1996 Dec; 39(26):5053-63. PubMed ID: 8978836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rosiglitazone: a clinical development focused on cardio-vascular prevention].
    Valensi P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
    Murao S; Hirata K; Ishida T; Takahara J
    Intern Med; 2000 Apr; 39(4):348-9. PubMed ID: 10801159
    [No Abstract]   [Full Text] [Related]  

  • 27. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
    Mukhtar R; Reckless JP
    Diabet Med; 2005 Jul; 22 Suppl 3():6-10. PubMed ID: 15960775
    [No Abstract]   [Full Text] [Related]  

  • 28. [Insulin-sensitizing agents].
    Kadowaki T
    Nihon Rinsho; 1999 Mar; 57(3):688-94. PubMed ID: 10199155
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypoglycemic agents to improve insulin resistance].
    Kadowaki T
    Nihon Rinsho; 2000 Feb; 58(2):283-90. PubMed ID: 10847809
    [No Abstract]   [Full Text] [Related]  

  • 30. [Dyslipidemia in insulin resistance and its improvement by troglitazone].
    Yagi K; Mabuchi H
    Nihon Rinsho; 2000 Feb; 58(2):426-9. PubMed ID: 10707570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive review of the antidiabetic agent rosiglitazone.
    Glazer NB; Cheatham WW
    Clin Ther; 2001 Feb; 23(2):307-8. PubMed ID: 11293563
    [No Abstract]   [Full Text] [Related]  

  • 32. Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
    Ota T; Osawa K
    Diabet Med; 2003 May; 20(5):420-1. PubMed ID: 12752495
    [No Abstract]   [Full Text] [Related]  

  • 33. Pioglitazone (Actos).
    Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
    [No Abstract]   [Full Text] [Related]  

  • 34. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone: the future.
    Brunetti P
    Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
    Mokale SN; Elgire RD; Sakle N; Shinde DB
    Bioorg Med Chem Lett; 2011 Jan; 21(2):682-5. PubMed ID: 21193309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The glitazones: proceed with caution.
    Krische D
    West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
    [No Abstract]   [Full Text] [Related]  

  • 38. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
    Hofmann CA; Colca JR
    Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
    [No Abstract]   [Full Text] [Related]  

  • 39. How should patients taking the discontinued diabetes drug troglitazone be managed?
    Reddy SS
    Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
    [No Abstract]   [Full Text] [Related]  

  • 40. Actos (pioglitazone).
    TreatmentUpdate; 2001; 13(7):5-6. PubMed ID: 11794862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.